Humoral immunity in diabetic pregnancy: interrelationships with maternal/neonatal complications and maternal metabolic control. 1985

F Fallucca, and U Di Mario, and P Gargiulo, and M Iavicoli, and C Galfo, and G Contreas, and A Pachi', and D Andreani

The presence of islet cell antibodies (ICA), complement fixing islet cell antibodies (CF-ICA), other organ-specific autoantibodies, insulin antibodies and two different types of immune complexes (AgAb) in diabetic pregnant women treated with insulin during pregnancy was investigated and compared with maternal metabolic control and with the course and outcome of pregnancy. One hundred and eighteen pregnant diabetic women were grouped according to type of diabetes: 56 were insulin-dependent diabetic patients who had been previously treated with insulin (Group 1); 23 were non-insulin-dependent diabetic patients who had previously received diet or oral treatment (Group 2); 39 had gestational diabetes (Group 3). 94 patients were subjected to regular check-ups during pregnancy and blood samples were taken during the last month of pregnancy (phase A); some were treated with standard preparations of insulin, the remainder with purified insulins. 24 patients were treated with purified insulins (a bovine and porcine mixture) on entering the study and blood samples were taken at regular intervals during pregnancy (phase B). ICA were detected in 12% of the patients in Group 1 and in 5% of those in Group 3. There was no significant variation in the titre during the gestational period. ICA were not detected in the patients in Group 2. No CF-ICA were found in any of the patients. The positivity of the other organ-specific autoantibodies was similar to that the normal control group. Insulin antibodies were found in concentrations of 67%, 73% and 25% in Groups 1,2 and 3 respectively during the last month of pregnancy.(ABSTRACT TRUNCATED AT 250 WORDS)

UI MeSH Term Description Entries
D007231 Infant, Newborn An infant during the first 28 days after birth. Neonate,Newborns,Infants, Newborn,Neonates,Newborn,Newborn Infant,Newborn Infants
D007232 Infant, Newborn, Diseases Diseases of newborn infants present at birth (congenital) or developing within the first month of birth. It does not include hereditary diseases not manifesting at birth or within the first 30 days of life nor does it include inborn errors of metabolism. Both HEREDITARY DISEASES and METABOLISM, INBORN ERRORS are available as general concepts. Neonatal Diseases,Disease, Neonatal,Diseases, Neonatal,Neonatal Disease
D007330 Insulin Antibodies Antibodies specific to INSULIN. Antibodies, Insulin
D007515 Islets of Langerhans Irregular microscopic structures consisting of cords of endocrine cells that are scattered throughout the PANCREAS among the exocrine acini. Each islet is surrounded by connective tissue fibers and penetrated by a network of capillaries. There are four major cell types. The most abundant beta cells (50-80%) secrete INSULIN. Alpha cells (5-20%) secrete GLUCAGON. PP cells (10-35%) secrete PANCREATIC POLYPEPTIDE. Delta cells (~5%) secrete SOMATOSTATIN. Islands of Langerhans,Islet Cells,Nesidioblasts,Pancreas, Endocrine,Pancreatic Islets,Cell, Islet,Cells, Islet,Endocrine Pancreas,Islet Cell,Islet, Pancreatic,Islets, Pancreatic,Langerhans Islands,Langerhans Islets,Nesidioblast,Pancreatic Islet
D011247 Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH. Gestation,Pregnancies
D011248 Pregnancy Complications Conditions or pathological processes associated with pregnancy. They can occur during or after pregnancy, and range from minor discomforts to serious diseases that require medical interventions. They include diseases in pregnant females, and pregnancies in females with diseases. Adverse Birth Outcomes,Complications, Pregnancy,Adverse Birth Outcome,Birth Outcome, Adverse,Complication, Pregnancy,Outcome, Adverse Birth,Pregnancy Complication
D011254 Pregnancy in Diabetics The state of PREGNANCY in women with DIABETES MELLITUS. This does not include either symptomatic diabetes or GLUCOSE INTOLERANCE induced by pregnancy (DIABETES, GESTATIONAL) which resolves at the end of pregnancy. Pregnancy in Diabetes,Pregnancy in Diabete,Pregnancy in Diabetic
D012016 Reference Values The range or frequency distribution of a measurement in a population (of organisms, organs or things) that has not been selected for the presence of disease or abnormality. Normal Range,Normal Values,Reference Ranges,Normal Ranges,Normal Value,Range, Normal,Range, Reference,Ranges, Normal,Ranges, Reference,Reference Range,Reference Value,Value, Normal,Value, Reference,Values, Normal,Values, Reference
D005260 Female Females
D006442 Glycated Hemoglobin Products of non-enzymatic reactions between GLUCOSE and HEMOGLOBIN (occurring as a minor fraction of the hemoglobin of ERYTHROCYTES.) It generally refers to glycated HEMOGLOBIN A. Hemoglobin A1c (Hb A1c) is hemoglobin A with GLYCATION on a terminal VALINE of the beta chain. Glycated hemoglobin A is used as an index of the average blood sugar level over a lifetime of erythrocytes. Fructated Hemoglobins,Glycohemoglobin,Glycohemoglobin A,Glycohemoglobins,Glycosylated Hemoglobin A,Hb A1c,HbA1,Hemoglobin A(1),Hemoglobin A, Glycosylated,Glycated Hemoglobin A,Glycated Hemoglobin A1c,Glycated Hemoglobins,Glycosylated Hemoglobin A1c,Hb A1,Hb A1a+b,Hb A1a-1,Hb A1a-2,Hb A1b,Hemoglobin, Glycated A1a-2,Hemoglobin, Glycated A1b,Hemoglobin, Glycosylated,Hemoglobin, Glycosylated A1a-1,Hemoglobin, Glycosylated A1b,A1a-1 Hemoglobin, Glycosylated,A1a-2 Hemoglobin, Glycated,A1b Hemoglobin, Glycated,A1b Hemoglobin, Glycosylated,Glycated A1a-2 Hemoglobin,Glycated A1b Hemoglobin,Glycosylated A1a-1 Hemoglobin,Glycosylated A1b Hemoglobin,Glycosylated Hemoglobin,Hemoglobin A, Glycated,Hemoglobin A1c, Glycated,Hemoglobin A1c, Glycosylated,Hemoglobin, Glycated,Hemoglobin, Glycated A1a 2,Hemoglobin, Glycosylated A1a 1,Hemoglobins, Fructated,Hemoglobins, Glycated

Related Publications

F Fallucca, and U Di Mario, and P Gargiulo, and M Iavicoli, and C Galfo, and G Contreas, and A Pachi', and D Andreani
July 1988, Diabetes research (Edinburgh, Scotland),
F Fallucca, and U Di Mario, and P Gargiulo, and M Iavicoli, and C Galfo, and G Contreas, and A Pachi', and D Andreani
February 2011, Best practice & research. Clinical obstetrics & gynaecology,
F Fallucca, and U Di Mario, and P Gargiulo, and M Iavicoli, and C Galfo, and G Contreas, and A Pachi', and D Andreani
January 1985, Antibiotics and chemotherapy,
F Fallucca, and U Di Mario, and P Gargiulo, and M Iavicoli, and C Galfo, and G Contreas, and A Pachi', and D Andreani
February 1981, JAMA,
F Fallucca, and U Di Mario, and P Gargiulo, and M Iavicoli, and C Galfo, and G Contreas, and A Pachi', and D Andreani
March 1981, Clinical obstetrics and gynecology,
F Fallucca, and U Di Mario, and P Gargiulo, and M Iavicoli, and C Galfo, and G Contreas, and A Pachi', and D Andreani
April 2018, Geburtshilfe und Frauenheilkunde,
F Fallucca, and U Di Mario, and P Gargiulo, and M Iavicoli, and C Galfo, and G Contreas, and A Pachi', and D Andreani
July 2021, Nature,
F Fallucca, and U Di Mario, and P Gargiulo, and M Iavicoli, and C Galfo, and G Contreas, and A Pachi', and D Andreani
April 2009, Seminars in fetal & neonatal medicine,
F Fallucca, and U Di Mario, and P Gargiulo, and M Iavicoli, and C Galfo, and G Contreas, and A Pachi', and D Andreani
January 1988, Minerva endocrinologica,
F Fallucca, and U Di Mario, and P Gargiulo, and M Iavicoli, and C Galfo, and G Contreas, and A Pachi', and D Andreani
April 2011, MMW Fortschritte der Medizin,
Copied contents to your clipboard!